Connection

Michael Hallek to Prospective Studies

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Prospective Studies.
Michael Hallek
Connection Strength
0.045
Prospective Studies
  1. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
    View in: PubMed
    Score: 0.031
  2. Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica. 2020 05; 105(5):1379-1390.
    View in: PubMed
    Score: 0.008
  3. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 09; 367(6):520-31.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.